DOCSLIB.ORG

Gabapentinoids in Chronic Pain

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gabapentinoids in Chronic Pain Gabapentinoids in Chronic Pain Stephanie Nichols, PharmD, BCPS, BCPP, FCCP [email protected] Introducing Penny Lane Medications • 53 year old female who presents to your Amlodipine 10mg daily practice after recently moving to Maine Aspirin 81mg daily from Arizona. • PMH: Hypertension, chronic back pain Calcium 500mg and vitamin D 1000 units BID related to a slipped disc, obesity, major Hydrocodone 5mg & acetaminophen 325mg TID depressive disorder, osteoporosis, CAD, alcohol use disorder, and pre-diabetes. Ibuprofen 400mg TID PRN pain • She presents for an early refill of her hydrocodone/acetaminophen and requests Lisinopril 20mg daily a dose increase for ongoing pain. You are Metformin ER 1000mg daily concerned about opioid induced hyperalgesia. Metoprolol XL 100mg daily Sertraline 100mg daily Opioid Induced Hyperalgesia: Patients on sufentanil displayed Control Sufentanil a lower threshold for pain and Sufentanil + withdrew more quickly to pain levobupivacaine stimuli versus controls Gomez-Brouchet et al. Journal of Translational Medicine 2015;13:208 Opioid Induced Hyperalgesia • Hyperalgesia (↓ pain tolerance) is important and real • Patients with OUD (+/- pharmacotherapy) have reduced pain tolerance • vs matched peers • vs siblings without OUD • ↓ by gabapentinoids and/or alpha 2 agonists? Ketamine? • With chronic pain, reducing opioid dose can alleviate this Alford, Ann Intern Med. 2006 Jan 17; 144(2): 127–134. Sirohi, J Pain Res. 2016; 9: 963–966. • Opioids are not the best option for neuropathic pain in general, and there are some signs of opioid induced hyperalgesia in Penny. • You plan to compassionately taper opioids in Penny and initiate an alternative treatment Non-Opioid Options • Adjunctive, non-opioid therapy • NSAIDs (oral or IV) or acetaminophen (APAP) (oral or IV) • Ibuprofen 400 mg plus APAP 1,000 mg is equivalent to one oxycodone/APAP 5/325 mg, hydrocodone/APAP 5/325 mg, or APAP/codeine 30/300mg tablet in acute lower extremity pain • Ibuprofen plus APAP is more effective than hydrocodone/APAP 5/325 mg for post-operative dental pain on systemic review • Epidurals and other peripheral nerve blocks • Topics agents: lidocaine patch, NSAID cream, menthol balm, capsaicin cream • Antidepressants (TCAs and SNRIs) • Gabapentinoids (gabapentin and pregabalin) 1. Chang, JAMA. 2017;318(17):1661–1667. 2. Moore, The Journal of the American Dental Association. 2013;144(8):898 – 908. Some Options for Penny • Non pharmacotherapy: acupuncture, Reiki, massage, PT, etc • Switch her antidepressant to an SNRI (or TCA) • Risk: worsening depression or intolerable noradrenergic or anticholinergic adverse effects • Schedule NSAID • Risk: worsen hypertension and risk of PUD with heavy alcohol use • Schedule acetaminophen • Risk: hepatotoxicity with heavy alcohol use • Prescribe lidocaine patch • Risk: inefficacy vs high cost • Prescribe gabapentin or pregabalin • Risk: sedation and edema After giving Penny the information, she elects to begin a gabapentinoid Dosing Considerations and Special Populations Gabapentin (Neurontin) Pregabalin (Lyrica) • Initial: 100 - 300mg daily to TID • Initial: 25 – 150mg/day (daily or BID) • Titrate up as tolerated • Titrate by 25 – 150mg/d in weekly or • Goal: 300 – 1200mg TID longer intervals • 900 – 3600mg per day • Goal: 300 – 600mg/day • Significantly reduce dose with CrCl • Divided BID to TID < 60ml/min • Max 1400mg/d for 30-59ml/min • Half dose with CrCl < 60ml/min, again when <30ml/min, and again when • No adjustment for hepatic <15ml/min impairment • Use caution in geriatric patients • No adjustment for hepatic impairment but use caution in geriatric patients Medication Formulations Gabapentin (Neurontin) Pregabalin (Lyrica) • Capsules • Capsules • 100mg, 300mg, 400mg • 25mg, 50mg, 75mg, 100mg • Tablet • 150mg, 200mg, 225mg, 300mg • 600mg, 800mg • Oral Solution • Oral solution • 20mg/ml • 50mg/ml • 24 hour extended release capsule • Long acting oral tablet (Gralise) (Lyrica CR) 82.5mg, 165mg, 330mg • 300mg, 600mg • Differences Between Pregabalin and Gabapentin • Both work by binding to the alph-2 delt-1 subunit of the L-type voltage gated calcium channels and modulating release of excitatory neurotransmitters • Presynaptic channels modulate the release of glutamate, norepinephrine, serotonin, dopamine, substance P, and calcitonin gene-related peptide • Both require facilitated transport across cellular membranes through system L- amino acid transporters (Dose-dependent and saturable process) • Gabapentin absorption is localized to the small intestine while pregabalin absorption extends to the ascending colon • Pregabalin is more completely absorbed while the absorption of gabapentin is more variable • Pregabalin bioavailability remains >90% at all therapeutic doses • Food delays absorption but fasting decreases AUC of XR product by 30% • Gabapentin bioavailability = 60% when dosed at 900mg/day and <33% at doses > 3600mg/day • Peak plasma levels of gabapentin occur 3 hours post dose • Rough dose equivalency: 450mg/day pregabalin is similar to 3600mg/day gabapentin Switching between the gabapentinoids • Dosages were switched using the following algorithm: • Gabapentin ≤900 mg/day → pregabalin 150mg/day • Gabapentin 901 mg/day to 1500 mg/day → pregabalin 225 mg/day • Gabapentin 1501 mg/day 2100 mg/day → pregabalin 300 mg/day • Gabapentin 2101 mg/day 2700 mg/day → pregabalin 450 mg/day • Gabapentin >2700 mg/day → pregabalin 600 mg/day • Gabapentin stopped after the nighttime dose and pregabalin started the following morning • This rapid change was generally well tolerated by patients She expresses a desire to try the cheapest option available. • Renal function is determined to be normal (CrCl > 60 ml/min) • Gabapentin is initiated at 100mg TID with a plan to increase to 200mg TID in 7 days and to 300mg TID another 7 days after that. You prescribe 100mg capsules. • You plan to follow up with Penny in 2 weeks to assess tolerability and effectiveness. At that visit, you plan to either increase the dose to 400mg TID or hold tight at 300mg TID and prescribe the 300mg capsules. You will follow up again with Penny in 3 months. Gabapentinoid Tolerability on Cochrane Review RR 95% CI Dizziness 1.99 1.94 – 3.37 Fatigue 1.85 1.12 – 3.05 Mentation Difficulties 3.34 1.54 – 7.25 Visual Disturbances 5.72 1.94 – 16.91 Monitoring • Renal function for dosing • Sedation and somnolence • Dizziness • Ocular disturbance (visual field loss or blurred vision) (pregabalin) • Up to 13% of patients • Suicidal ideation • Myopathy or muscle weakness or pain (pregabalin) • Edema or weight gain (pregabalin) • Up to 16% of patients Penny Lane Returns Medications Amlodipine 10mg daily • 56 year old female who re-presents Aspirin 81mg daily to your practice after visiting her family “back home” for the past Calcium 500mg and vitamin D 1000 units BID several months. Gabapentin 300mg TID • She presents for a refill of all her medications and a yearly check-up. Ibuprofen 400mg TID PRN pain • PMH: Hypertension, chronic back Lisinopril 40mg daily pain, obesity, major depressive Metformin ER 1000mg daily disorder, osteoporosis, CAD s/p MI, alcohol use disorder, and pre- Metoprolol XL 200mg daily diabetes. Pregabalin 100mg TID Sertraline 100mg daily What is your concern with Penny’s medication list? Medications Amlodipine 10mg daily Aspirin 81mg daily Calcium 500mg and vitamin D 1000 units BID Gabapentin 300mg TID Ibuprofen 400mg TID PRN pain Lisinopril 40mg daily Metformin ER 1000mg daily Metoprolol XL 200mg daily Pregabalin 100mg TID Sertraline 100mg daily • There is no therapeutic indication for multiple gabapentinoids at the same time and they compete for the same transporter for absorption • Best to pick one agent and optimize it • In Penny, we can stop the gabapentin 300mg TID and replace with another 50mg TID of pregabalin for a new dose of 150mg TID. This switch can be abrupt. • Educate Penny about gapapentin expectations and pain threshold • Moving the threshold up vs eliminating pain Medications Penny Lane Return Yet Again Amlodipine 10mg daily Aspirin 81mg daily • 59 year old female who re-presents Calcium 500mg & vitamin D 1000 units BID to your practice after being Furosemide 80mg BID hospitalized with new onset heart failure with reduced ejection Ibuprofen 400mg TID PRN pain fraction (35%). Lisinopril 40mg daily • PMH: Hypertension, chronic back Metformin ER 1000mg daily pain, obesity, major depressive disorder, osteoporosis, CAD s/p MI, Metoprolol XL 200mg daily HF with reduced EF (35%), alcohol Pregabalin 150mg TID use disorder, and pre-diabetes. Sertraline 100mg daily Spironolactone 50mg daily What is your concern with Penny’s medication list at this point? Medications Amlodipine 10mg daily Aspirin 81mg daily Calcium 500mg & vitamin D 1000 units BID Furosemide 80mg BID Ibuprofen 400mg TID PRN pain Lisinopril 40mg daily Metformin ER 1000mg daily Metoprolol XL 200mg daily Pregabalin 150mg TID Sertraline 100mg daily Spironolactone 50mg daily Pregabalin and Heart Failure • Edema and cardiac congestion can occur in up to 16% of patients • Peripheral edema followed by central edema • New York Heart Association issued a warning about using caution when prescribing pregabalin to type III-IV heart failure patients • Case reports of pregabalin induced heart failure • Avoid combining with TZDs (eg. pioglitasone) • Risk is also present with gabapentin • 1.2% vs 1.3% risk in a study of nearly 20,000 patients >65 years old HO JM et al. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1087-1092. Penny’s plan • Taper off pregabalin
Load more

Recommended publications
  • Métrologie De La Douleur Animale Sur Modèles Expérimentaux : Développement Et Validation De Biomarqueurs Neuroprotéomiques
    Université de Montréal Métrologie de la douleur animale sur modèles expérimentaux : développement et validation de biomarqueurs neuroprotéomiques. par Colombe Otis Département de biomédecine vétérinaire Faculté de médecine vétérinaire Thèse présentée à la Faculté de médecine vétérinaire en vue de l’obtention du grade de philosophiæ doctor (Ph. D.) en sciences vétérinaires option pharmacologie Août, 2017 © Colombe Otis, 2017 Résumé La douleur est un phénomène complexe et dynamique comprenant un processus primaire et sensoriel, la nociception, auquel se rajoutent des réactions de défense et d'alarme psychophysiologiques. Ceci conduit au développement d'une véritable mémoire de la douleur, individuelle et modulée (plasticité neuronale) par des expériences précédentes de douleur, incluant entre autres, des phénomènes de sensibilisation nociceptive. Pour bien comprendre les mécanismes de sensibilisation centrale, les modèles animaux mimant les pathologies humaines sont d’une importance primordi ale. Or, pour ce faire, nous avons proposé une série d'approches expérimentales translationnelles par le développement de modèles expérimentaux de douleur bovine, canine et murine afin de caractériser les atteintes du protéome spinal en fonction du niveau de douleur perçu par l'animal et d’identifier le (les) marqueur (s) potentiellement modulé (s) par la sensibilisation nociceptive. À l’aide de la neuroprotéomique, nous avons identifié sur un modèle bovin de douleur viscérale, la protéine transthyrétine (TTR) comme étant sous-exprimée dans le protéome spinal en présence de douleur et ce, vérifié également dans le modèle canin de douleur chronique liée à l’arthrose chirurgicale. Ces résultats suggèrent la possibilité d’entrevoir la TTR comme un biomarqueur potentiel de la douleur chronique. Notre découverte de la relation entre les niveaux spinaux de TTR par neuroprotéomique et l’ hypersensibilité à la douleur dans les modèles bovin et canin soutiennent l’implication de composantes inflammatoires nociceptives et immunitaires.
    [Show full text]
  • Gabapentin Abuse Gabapentin (Neurontin®) Is Indicated for the Treatment of Epilepsy and Neuro- Pathic Pain, Including Post-Herpetic Neuralgia
    November 2018 Poison Center Hotline: 1-800-222-1222 The Maryland Poison Center’s Monthly Update: News, Advances, Information Gabapentin Abuse Gabapentin (Neurontin®) is indicated for the treatment of epilepsy and neuro- pathic pain, including post-herpetic neuralgia. Gabapentin is often prescribed off -label for a variety of conditions including insomnia, anxiety, bipolar disorder, migraines, drug and alcohol addiction, and others. Off-label use exceeds use for FDA approved indications. Termed a gabapentinoid, it is an analog of γ- aminobutyric acid (GABA) that increases GABA but does not bind to GABA re- ceptors. It has a selective inhibitory effect on voltage-gated calcium channels containing the α2δ1 subunit. Its exact mechanism for epilepsy and pain is un- clear. Gabapentin is not a controlled substance as it was believed that gabapentin had no abuse potential when approved by the FDA in 1993. Overall, if used at thera- Did you know? peutic doses by patients without a substance abuse/misuse history, the risk of misuse is probably lower than that of other drugs such as benzodiazepines. There are reports of abuse of However, reports are increasing of gabapentin misuse and abuse. Motivations pregabalin (Lyrica ®), another for misuse include recreational use, mood and/or anxiety control, potentiating gabapentinoid used for the effects of drug abuse treatment, pain management, reducing cravings for neuropathic pain, post-herpetic other drugs, managing withdrawal from other drugs, substituting for other pain and fibromyalgia. drugs, and gabapentin addiction (Addiction 2016;11:1160-74). The risk of misuse Approved by the FDA in 2004, increases in people with a history of recreational drug abuse who take gabapen- pregabalin is Schedule V.
    [Show full text]
  • Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review
    Current Pain and Headache Reports (2019) 23: 37 https://doi.org/10.1007/s11916-019-0774-0 OTHER PAIN (A KAYE AND N VADIVELU, SECTION EDITORS) Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Omar Viswanath1,2,3 & Ivan Urits4 & Mark R. Jones4 & Jacqueline M. Peck5 & Justin Kochanski6 & Morgan Hasegawa6 & Best Anyama7 & Alan D. Kaye7 Published online: 1 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Neuropathic pain is often debilitating, severely limiting the daily lives of patients who are affected. Typically, neuropathic pain is difficult to manage and, as a result, leads to progression into a chronic condition that is, in many instances, refractory to medical management. Recent Findings Gabapentinoids, belonging to the calcium channel blocking class of drugs, have shown good efficacy in the management of chronic pain and are thus commonly utilized as first-line therapy. Various sodium channel blocking drugs, belonging to the categories of anticonvulsants and local anesthetics, have demonstrated varying degrees of efficacy in the in the treatment of neurogenic pain. Summary Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain. Keywords Neuropathic pain . Chronic pain . Ion Channel blockers . Anticonvulsants . Membrane stabilizers Introduction Neuropathic pain, which is a result of nervous system injury or lives of patients who are affected. Frequently, it is difficult to dysfunction, is often debilitating, severely limiting the daily manage and as a result leads to the progression of a chronic condition that is, in many instances, refractory to medical This article is part of the Topical Collection on Other Pain management.
    [Show full text]
  • Gabapentinoids: Pharmacokinetics, Pharmacodynamics and Considerations for Clinical Practice
    912496BJP British Journal of PainChincholkar Special Issue Article British Journal of Pain 1 –11 Gabapentinoids: pharmacokinetics, © The British Pain Society 2020 Article reuse guidelines: sagepub.com/journals-permissions pharmacodynamics and considerations DOI:https://doi.org/10.1177/2049463720912496 10.1177/2049463720912496 for clinical practice journals.sagepub.com/home/bjp Mahindra Chincholkar Abstract The gabapentinoids are often recommended as first-line treatments for the management of neuropathic pain. The differing pharmacodynamic and pharmacokinetic profiles can have implications for clinical practice. This article has summarised these key differences. In addition to their use in managing neuropathic pain, gabapentinoids are increasingly being used for off-label conditions despite the lack of evidence. Prescription rates for off-label conditions have overtaken that for on-label use. Similarly, the use of gabapentinoids in the perioperative period is now embedded in clinical practice despite conflicting evidence. This article summarises the risks associated with this increasing use. There is increasing evidence of the potential to cause harm in vulnerable populations such as the elderly and increasing prevalence of abuse. The risk of respiratory depression in combination with opioids is of particular concern in the context of the current opioid crisis. This article describes the practical considerations involved that might help guide appropriate prescribing practices. Keywords Gabapentin, pregabalin, pain management, adverse effects, pharmacology Introduction movement, sleep disorders, headaches, alcohol with- drawal syndrome, chronic back pain, fibromyalgia, vis- The gabapentinoid drugs gabapentin and pregabalin ceral pain and acute postoperative pain.4,5 The rate of are antiepileptic drugs that are considered as first-line new prescriptions is increasing and tripled in England 1 treatments for the management of neuropathic pain.
    [Show full text]
  • 1 Gabapentinoids in Total Joint Arthroplasty: the Clinical Practice
    1 Gabapentinoids in Total Joint Arthroplasty: The Clinical Practice Guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society Charles P. Hannon MD1, Yale A. Fillingham MD2, James A. Browne MD3, Emil H Schemitsch MD FRCS(C)4, AAHKS Anesthesia & Analgesia Clinical Practice Guideline Workgroup5, Asokumar Buvanendran MD6, William G. Hamilton MD7*, Craig J. Della Valle MD1* 1Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA 2Department of Orthopaedic Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA 3Department of Orthopaedic Surgery, University of Virginia, Charlottesville, VA, USA 4Department of Surgery, University of Western Ontario, London, Ontario, Canada 5Workgroup Comprised of the following individuals: Justin T. Deen MD (Department of Orthopaedics and Rehabilitation, University of Florida College of Medicine, Gainesville, FL, USA), Greg A. Erens MD (Department of Orthopaedic Surgery, Emory University, Atlanta, GA, USA), Jess H. Lonner MD (Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA), Aidin E. Pour MD (Department of orthopaedic surgery, University of Michigan, Ann Arbor, MI, USA), Robert S. Sterling MD (Department of Orthopedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA) 6Department of Anesthesiology, Rush University Medical Center, Chicago, IL, USA 7Anderson Orthopedic Research Institute, Alexandria, VA, USA *Denotes co-senior authors 2 Introduction The American Association of Hip and Knee Surgeons (AAHKS), The American Academy of Orthopaedic Surgeons (AAOS), The Hip Society, The Knee Society and The American Society of Regional Anesthesia and Pain Medicine (ASRA) have worked together to develop evidence-based guidelines on the use of gabapentinoids in primary total joint arthroplasty (TJA).
    [Show full text]
  • 2020 Incentive Formularies
    2020 Incentive Formularies: This Incentive Formulary applies to members of an employer/retiree, union, or trust fund health plan For Medicare Part D: 5 Tier Incentive Formulary Please click here. For Medicare Part D: Prior Authorization Criteria Please click here. For Medicare Part D: Step Therapy Criteria Please click here. Formulary ID: 20133 Version: 22 Updated: 12/2020 Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Highmark Senior Health Company, Highmark Choice Company, Highmark Senior Solutions Company or HM Health Insurance Company. When it refers to “plan” or “our plan,” it means Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP. This document includes a list of the drugs (formulary) for our plan which is current as of 12/1/2020. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2020, and from time to time during the year. What is the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary? A formulary is a list of covered drugs selected by Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program.
    [Show full text]
  • State of the Art Opioid-Sparing Strategies for Post-Operative Pain in Adult Surgical Patients
    UC San Diego UC San Diego Previously Published Works Title State of the art opioid-sparing strategies for post-operative pain in adult surgical patients. Permalink https://escholarship.org/uc/item/3z9800kv Journal Expert opinion on pharmacotherapy, 20(8) ISSN 1465-6566 Authors Gabriel, Rodney A Swisher, Matthew W Sztain, Jacklynn F et al. Publication Date 2019-06-01 DOI 10.1080/14656566.2019.1583743 Peer reviewed eScholarship.org Powered by the California Digital Library University of California EXPERT OPINION ON PHARMACOTHERAPY https://doi.org/10.1080/14656566.2019.1583743 REVIEW State of the art opioid-sparing strategies for post-operative pain in adult surgical patients Rodney A. Gabriela,b,c, Matthew W. Swishera,c, Jacklynn F. Sztaina, Timothy J. Furnisha, Brian M. Ilfelda,c and Engy T. Saida aDepartment of Anesthesiology, Division of Regional Anesthesia and Acute Pain, University of California, San Diego, La Jolla, CA, USA; bDivision of Biomedical Informatics, University of California, San Diego, La Jolla, CA, USA; cOutcomes Research Consortium, Cleveland, OH, USA ABSTRACT ARTICLE HISTORY Introduction: There are various important implications associated with poorly controlled postoperative Received 17 October 2018 pain in the adult surgical patient – this includes cardiopulmonary complications, opioid-related side Accepted 13 February 2019 effects, unplanned hospital admissions, prolonged hospital stay, and the subsequent development of KEYWORDS chronic pain or opioid addiction. With the ongoing national opioid crisis, it is imperative that perio- Multimodal analgesia; acute perative providers implement pathways for surgical patients that reduce opioid requirements and pain- pain service; opioid; related complications. perioperative Areas covered: In this review, the authors discuss the components of a multimodal opioid-sparing analgesia pathway as it pertains to the perioperative environment.
    [Show full text]
  • Gabapentin Misuse, Abuse, and Diversion: a Systematic Review
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Addiction Manuscript Author . Author manuscript; Manuscript Author available in PMC 2017 August 29. Published in final edited form as: Addiction. 2016 July ; 111(7): 1160–1174. doi:10.1111/add.13324. Gabapentin misuse, abuse, and diversion: A systematic review Rachel V. Smith, MPH1,2,3, Jennifer R. Havens, PhD, MPH1,2, and Sharon L. Walsh, PhD1,4,5,* 1Center on Drug and Alcohol Research, Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY 2Department of Epidemiology, University of Kentucky College of Public Health, Lexington, KY 3Department of Biostatistics, University of Kentucky College of Public Health, Lexington, KY 4Department of Pharmacology, University of Kentucky College of Medicine, Lexington, KY 5Department of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, KY Abstract Background and Aims—Since its market release, gabapentin has been presumed to have no abuse potential and subsequently has been prescribed widely off-label, despite increasing reports of gabapentin misuse. This review estimates and describes the prevalence and effects of, motivations behind, and risk factors for gabapentin misuse, abuse, and diversion. Methods—Databases were searched for peer-reviewed articles demonstrating gabapentin misuse, characterized by taking a larger dosage than prescribed or taking gabapentin without a prescription, and diversion. All types of studies were considered; grey literature was excluded. Thirty-three articles met inclusion criteria, consisting of 23 case studies and 11 epidemiological reports. Published reports came from the USA, the UK, Germany, Finland, India, South Africa, and France, and two analyzed websites not specific to a particular country.
    [Show full text]
  • Characterization of Hospitalized Patients Who Received Naloxone While Receiving Opioids with Or Without Gabapentinoids
    ORIGINAL RESEARCH Open Access Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids Payal H. Desai, PharmD, BCCCP1; Olesya Taylor, PharmD, BCPS2; Kunal J. Shah, PharmD3; 4 5 Kirk E. Evoy, PharmD, BCACP, BC-ADM, CTTS ; Alyssa M. Peckham, PharmD, BCPP Downloaded from http://meridian.allenpress.com/mhc/article-pdf/11/4/225/2868688/i2168-9709-11-4-225.pdf by guest on 02 October 2021 How to cite: Desai PH, Taylor O, Shah KJ, Evoy KE, Peckham AM. Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. Ment Health Clin [Internet]. 2021;11(4):225-30. DOI: 10.9740/mhc.2021.07.225. Submitted for Publication: August 11, 2020; Accepted for Publication: April 9, 2021 Abstract Introduction: Gabapentin and pregabalin (gabapentinoids) can be given with opioids for opioid-sparing and adjuvant analgesic effects. In the context of certain comorbidities and high dosages, coadministration of these agents can lead to respiratory depression or oversedation, necessitating naloxone administration. Methods: A retrospective chart review from January 2015 to December 2017 was conducted to include patients who received naloxone and opioids with or without gabapentinoids. Exclusion criteria included pregnancy or having received naloxone in the emergency department, intensive care, or pediatrics units. The primary outcome was to characterize differences between groups regarding comorbidities, history of renal or hepatic dysfunction, history of SUD, opioid tolerance, initiation and dose appropriateness of gabapentinoids, and dose intensity of gabapentinoids and opioids. Secondary outcomes were concomitant CNS depressant use and naloxone episodes for documented respiratory depression. Results: Of 126 patients who met inclusion criteria, 36 received opioids and gabapentinoids (gabapentinoid group) and 90 received opioids alone (nongabapentinoid group).
    [Show full text]
  • The Toxicology Investigators Consortium Case Registry—The 2017 Annual Report
    Journal of Medical Toxicology (2018) 14:182–211 https://doi.org/10.1007/s13181-018-0679-z ORIGINAL ARTICLE The Toxicology Investigators Consortium Case Registry—the 2017 Annual Report Lynn A. Farrugia1 & Sean H. Rhyee2 & Sharan L. Campleman3 & Bryan Judge4 & Louise Kao5 & Anthony Pizon6 & Lauren Porter 7 & Anne M. Riederer3 & Timothy Wiegand8 & Diane Calello9 & Paul M. Wax10 & Jeffrey Brent11 & On behalf of the Toxicology Investigators Consortium (ToxIC) Study Group Received: 12 July 2018 /Revised: 19 July 2018 /Accepted: 20 July 2018 /Published online: 9 August 2018 # American College of Medical Toxicology 2018 Abstract The Toxicology Investigators Consortium (ToxIC) Case Registry was established by the American College of Medical Toxicology in 2010. The Registry collects data from participating sites with the agreement that all bedside medical toxicology consultations will be entered. The objective of this eighth annual report is to summarize the Registry’s 2017 data and activity with its additional 7577 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2017. Detailed data was collected from these cases and aggregated to provide information which includes demographics (e.g., age, gender, race, ethnicity), reason for medical toxicology evaluation (e.g., intentional pharma- ceutical exposure, envenomation, withdrawal from a substance), agent and agent class, clinical signs and symptoms (e.g., vital sign abnormalities, organ system dysfunction), treatments and antidotes administered, fatality, and life support withdrawal data. Females were involved in 50.4% of cases. Transgender demographic information collection was initiated in 2017 to better represent the population and there were 36 cases involving transgender patients.
    [Show full text]
  • Neuropathic Pain in Serious Medical Illness
    Interprofessional Webinar Series Drug Therapy for Neuropathic Pain in the Medically Ill Russell K. Portenoy, MD Executive Director, MJHS Institute for Innovation in Palliative Care Chief Medical Officer, MJHS Hospice and Palliative Care Professor of Neurology, Albert Einstein College of Medicine Financial Disclosures Russell K. Portenoy, MD, Planner/Speaker, has indicated a relationship with the following: Pfizer Inc. (grant to department). Any discussion of investigational or unlabeled uses of a product will be identified. No other Planning Committee Member has any disclosures. Neuropathic Pain in Serious Medical Illness • Definition and epidemiology • Mechanisms • Assessment • Treatment Cancer-Related Neuropathic Pain: Definitional Challenges • Changing Definitions . Older: Pain from a lesion or dysfunction of the nervous system . Newer: Pain caused by lesion or disease of the somatosensory nervous system http://www.iasp-pain.org/Content/NavigationMenu/GeneralResourceLinks/PainDefinitions/default.htm Neuropathic Pain: Epidemiology • 1 – 6% overall prevalence in the general population • 19% – 39% of patients with cancer pain • In general, associated with high illness burden and health care utilization Attal N, et al, Pain, 2011;152:2836; Bennett et al, Pain, 2012;153:359; Smith BH, Torrance N, Curr Pain Headache Rep 2012;16:191. Neuropathic Pain: Mechanisms • Multiple mechanisms, which may vary by . Medical diagnosis . Site of neurological lesion . Inferred pathophysiology . Other factors Neuropathic Pain: Variation • Examples of medical
    [Show full text]
  • WO 2017/172603 Al 5 October 2017 (05.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/172603 Al 5 October 2017 (05.10.2017) P O P C T (51) International Patent Classification: c/o Tioga Research, Inc., 6330 Nancy Ridge Drive, Suite A61K 31/197 (2006.01) A61K 31/00 (2006.01) 102, San Diego, California 92121 (US). A61K 9/00 (2006.01) A61K 31/195 (2006.01) (74) Agents: TANNER, Lorna L. et al; SHEPPARD MUL- A61K 9/06 (2006.01) LIN RICHTER & HAMPTON LLP, 379 Lytton Avenue, (21) International Application Number: Palo Alto, California 94301-1479 (US). PCT/US20 17/024281 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 27 March 2017 (27.03.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/390,369 28 March 2016 (28.03.2016) US NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (71) Applicant: TIOGA RESEARCH, INC. [US/US]; 6330 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, Nancy Ridge Drive, Suite 102, San Diego, California TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 9212 1 (US).
    [Show full text]